10-K Filing

INSIGHT MOLECULAR DIAGNOSTICS INC. CIK: 1642380 FY 2020

Filing Information

Form Type	10-K
Accession Number	`0001493152-21-006465`
Period End Date	20201231
Filing Date	20210319
Fiscal Year	2020
Fiscal Period	FY
XBRL Instance	ocx-20201231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 72 Income Statement 38 Cash Flow Statement 100 Stockholders Equity 27 Comprehensive Income 6

Balance Sheet 72 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock, no par value	`PreferredStockNoParValue`	-	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	5.00M	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$22.07M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	-	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$7.14M	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	-	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$203.00K	USD	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	-	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$675.00K	USD	Point-in-time
Common stock, no par value	`CommonStockNoParValue`	-	USD	Point-in-time
Marketable equity securities	`EquitySecuritiesFvNi`	$379.00K	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.21M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	150.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	150.00M	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$505.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$9.23M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	69.12M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	57.03M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$22.96M	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	69.12M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	57.03M	shares	Point-in-time
Right-of-use assets, machinery and equipment, net and construction in progress	`RightofuseAssetsMachineryAndEquipmentNet`	$6.52M	USD	Point-in-time
Right-of-use assets, machinery and equipment, net and construction in progress	`RightofuseAssetsMachineryAndEquipmentNet`	$3.73M	USD	Point-in-time
Equity method investment in Razor	`EquityMethodInvestments`	$10.96M	USD	Point-in-time
Equity method investment in Razor	`EquityMethodInvestments`	$13.42M	USD	Point-in-time
Goodwill	`Goodwill`	$9.19M	USD	Point-in-time
Goodwill	`Goodwill`	-	USD	Point-in-time
Goodwill	`Goodwill`	$9.19M	USD	Point-in-time
Intangibles, net	`IntangibleAssetsNetExcludingGoodwill`	-	USD	Point-in-time
Intangibles, net	`IntangibleAssetsNetExcludingGoodwill`	$15.01M	USD	Point-in-time
Deposits and other noncurrent assets	`DepositsAndOtherNoncurrentAssets`	$2.21M	USD	Point-in-time
Deposits and other noncurrent assets	`DepositsAndOtherNoncurrentAssets`	$2.06M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$39.86M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$55.42M	USD	Point-in-time
Amount due to Lineage and affiliates	`DueToRelatedPartiesCurrent`	$6.00K	USD	Point-in-time
Amount due to Lineage and affiliates	`DueToRelatedPartiesCurrent`	-	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$469.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$432.00K	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$5.75M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccountsPayableAndOtherAccruedLiabilitiesCurrent`	$2.61M	USD	Point-in-time
Loan payable, current	`LoansPayableCurrent`	$1.12M	USD	Point-in-time
Loan payable, current	`LoansPayableCurrent`	$2.39M	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`OperatingLeaseAndFinancingLeaseLiabilitiesCurrent`	$422.00K	USD	Point-in-time
Right-of-use and financing lease liabilities, current	`OperatingLeaseAndFinancingLeaseLiabilitiesCurrent`	$230.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$4.44M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$9.00M	USD	Point-in-time
Loan payable, net of deferred financing costs, noncurrent	`LongTermLoansPayable`	$1.51M	USD	Point-in-time
Loan payable, net of deferred financing costs, noncurrent	`LongTermLoansPayable`	$1.91M	USD	Point-in-time
Right-of-use and financing lease liabilities, noncurrent	`OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent`	$4.31M	USD	Point-in-time
Right-of-use and financing lease liabilities, noncurrent	`OperatingLeaseLiabilitiesAndFinancingLeaseLiabilitiesNonCurrent`	$2.68M	USD	Point-in-time
Contingent consideration liabilities	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	$7.12M	USD	Point-in-time
Contingent consideration liabilities	`BusinessCombinationContingentConsiderationLiabilityNoncurrent`	-	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$9.02M	USD	Point-in-time
TOTAL LIABILITIES	`Liabilities`	$21.94M	USD	Point-in-time
Commitments and contingencies (Note 14)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 14)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, no par value, 150,000 shares authorized; 69,117 and 57,032 shares issued and outstanding at December 31, 2020 and 2019, respectively	`CommonStockValue`	$157.16M	USD	Point-in-time
Common stock, no par value, 150,000 shares authorized; 69,117 and 57,032 shares issued and outstanding at December 31, 2020 and 2019, respectively	`CommonStockValue`	$124.58M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-93.75M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-123.68M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$3.42M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$30.84M	USD	Point-in-time
Total shareholders' equity	`StockholdersEquity`	$33.48M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$39.86M	USD	Point-in-time
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	`LiabilitiesAndStockholdersEquity`	$55.42M	USD	Point-in-time

Income Statement 38 line items

Line Item	Tag	Value	Unit	Period
Total revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.22M	USD	Annual
Total revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	-	USD	Annual
Cost of revenues	`CostOfRevenue`	-	USD	Annual
Cost of revenues	`CostOfRevenue`	$1.85M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$9.80M	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$6.79M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$16.79M	USD	Annual
General and administrative	`GeneralAndAdministrativeExpense`	$13.28M	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$2.16M	USD	Annual
Sales and marketing	`SellingAndMarketingExpense`	$6.49M	USD	Annual
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-4.01M	USD	Annual
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	-	USD	Annual
Total costs and operating expenses	`CostsAndOperatingExpenses`	$30.93M	USD	Annual
Total costs and operating expenses	`CostsAndOperatingExpenses`	$22.24M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-22.24M	USD	Annual
Loss from operations	`OperatingIncomeLoss`	$-29.71M	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-153.00K	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Interest income (expense), net	`InterestIncomeExpenseNet`	$299.00K	USD	Annual
Interest income (expense), net	`InterestIncomeExpenseNet`	$-252.00K	USD	Annual
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$297.00K	USD	Annual
Unrealized gain (loss) on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-49.00K	USD	Annual
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-281.00K	USD	Annual
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-1.55M	USD	Annual
Other income (expenses), net	`OtherNonoperatingIncomeExpense`	$-3.00K	USD	Annual
Other income (expenses), net	`OtherNonoperatingIncomeExpense`	$27.00K	USD	Annual
Total other expenses, net	`NonoperatingIncomeExpense`	$-1.48M	USD	Annual
Total other expenses, net	`NonoperatingIncomeExpense`	$-187.00K	USD	Annual
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-31.19M	USD	Annual
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-22.43M	USD	Annual
Income tax benefit	`IncomeTaxExpenseBenefit`	$-1.25M	USD	Annual
Income tax benefit	`IncomeTaxExpenseBenefit`	-	USD	Annual
NET LOSS	`NetIncomeLoss`	$-22.43M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-29.93M	USD	Annual
Net loss per share; basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.44	USD	Annual
Net loss per share; basic and diluted	`EarningsPerShareBasicAndDiluted`	$-0.46	USD	Annual
Weighted average shares outstanding; basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	65.48M	shares	Annual
Weighted average shares outstanding; basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	51.30M	shares	Annual

Cash Flow Statement 100 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-22.43M	USD	Annual
Net loss	`NetIncomeLoss`	$-29.93M	USD	Annual
Depreciation expense	`Depreciation`	$344.00K	USD	Annual
Depreciation expense	`Depreciation`	$313.00K	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	-	USD	Annual
Amortization of intangible assets	`AmortizationOfIntangibleAssets`	$81.00K	USD	Annual
Amortization of right-of-use assets and liabilities	`AmortizationOfRightOfUseAssetsAndLiabilities`	$7.00K	USD	Annual
Amortization of right-of-use assets and liabilities	`AmortizationOfRightOfUseAssetsAndLiabilities`	$1.50M	USD	Annual
Impairment charge for long-lived assets	`ImpairmentOfLongLivedAssetsToBeDisposedOf`	-	USD	Annual
Impairment charge for long-lived assets	`ImpairmentOfLongLivedAssetsToBeDisposedOf`	$422.00K	USD	Annual
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-281.00K	USD	Annual
Pro rata loss from equity method investment in Razor	`IncomeLossFromEquityMethodInvestments`	$-1.55M	USD	Annual
Amortization of prepaid maintenance	`AmortizationOfPrepaidMaintenance`	$37.00K	USD	Annual
Amortization of prepaid maintenance	`AmortizationOfPrepaidMaintenance`	$74.00K	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$5.07M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$3.00M	USD	Annual
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$297.00K	USD	Annual
Unrealized (gain) loss on marketable equity securities	`MarketableSecuritiesUnrealizedGainLoss`	$-49.00K	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$102.00K	USD	Annual
Amortization of debt issuance costs	`AmortizationOfFinancingCosts`	$59.00K	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	$-153.00K	USD	Annual
Loss on extinguishment of debt	`GainsLossesOnExtinguishmentOfDebt`	-	USD	Annual
Warrants issued for advisory services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	$234.00K	USD	Annual
Warrants issued for advisory services	`IssuanceOfStockAndWarrantsForServicesOrClaims`	-	USD	Annual
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	$-4.01M	USD	Annual
Change in fair value of contingent consideration	`BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1`	-	USD	Annual
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	-	USD	Annual
Deferred income tax benefit	`DeferredIncomeTaxExpenseBenefit`	$-1.25M	USD	Annual
Other	`OtherOperatingActivitiesCashFlowStatement`	$5.00K	USD	Annual
Other	`OtherOperatingActivitiesCashFlowStatement`	$107.00K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$182.00K	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	-	USD	Annual
Amount due to Lineage and affiliates	`IncreaseDecreaseInDueToRelatedParties`	$-2.09M	USD	Annual
Amount due to Lineage and affiliates	`IncreaseDecreaseInDueToRelatedParties`	$-6.00K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$202.00K	USD	Annual
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$267.00K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$854.00K	USD	Annual
Accounts payable and accrued liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$741.00K	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-25.98M	USD	Annual
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-19.71M	USD	Annual
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	-	USD	Annual
Acquisition of Insight Genetics, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$6.19M	USD	Annual
Deposits paid for the Chronix merger agreement	`PaymentForDeposits`	-	USD	Annual
Deposits paid for the Chronix merger agreement	`PaymentForDeposits`	$325.00K	USD	Annual
Equity method investment in Razor	`PaymentsToAcquireEquityMethodInvestments`	$11.24M	USD	Annual
Equity method investment in Razor	`PaymentsToAcquireEquityMethodInvestments`	$4.00M	USD	Annual
Purchases of furniture and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$1.23M	USD	Annual
Purchases of furniture and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$918.00K	USD	Annual
Security deposit and other	`ProceedsFromSecurityDepositAndOther`	$-252.00K	USD	Annual
Security deposit and other	`ProceedsFromSecurityDepositAndOther`	$-7.00K	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-11.75M	USD	Annual
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-12.41M	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$1.45M	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$943.00K	USD	Annual
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$18.34M	USD	Annual
Proceeds from sale of common shares	`ProceedsFromIssuanceOfCommonStock`	$48.85M	USD	Annual
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$3.29M	USD	Annual
Financing costs to issue common shares	`PaymentsOfStockIssuanceCosts`	$58.00K	USD	Annual
Proceeds from sale of common shares under at-the-market transactions	`ProceedsFromIssuanceOfPrivatePlacement`	-	USD	Annual
Proceeds from sale of common shares under at-the-market transactions	`ProceedsFromIssuanceOfPrivatePlacement`	$2.46M	USD	Annual
Financing costs for at-the-market sales	`PaymentForFinancingCostsForAtthemarketSales`	$74.00K	USD	Annual
Financing costs for at-the-market sales	`PaymentForFinancingCostsForAtthemarketSales`	-	USD	Annual
Common shares received and retired for employee taxes paid	`CommonSharesReceivedAndRetiredForEmployeeTaxesPaid`	$14.00K	USD	Annual
Common shares received and retired for employee taxes paid	`CommonSharesReceivedAndRetiredForEmployeeTaxesPaid`	-	USD	Annual
Proceeds from refinance of bank loan	`ProceedsFromBankDebt`	$3.00M	USD	Annual
Proceeds from refinance of bank loan	`ProceedsFromBankDebt`	-	USD	Annual
Payoff of principal and bank fees from refinancing of bank loan	`RepaymentOfPrincipalAndBankFeesFromRefinancingOfBankLoan`	-	USD	Annual
Payoff of principal and bank fees from refinancing of bank loan	`RepaymentOfPrincipalAndBankFeesFromRefinancingOfBankLoan`	$516.00K	USD	Annual
Repayment of principal of loan payable prior to refinancing	`RepaymentsOfLongTermLinesOfCredit`	$667.00K	USD	Annual
Repayment of principal of loan payable prior to refinancing	`RepaymentsOfLongTermLinesOfCredit`	$375.00K	USD	Annual
Repayment of financing lease obligations	`FinanceLeasePrincipalPayments`	$454.00K	USD	Annual
Repayment of financing lease obligations	`FinanceLeasePrincipalPayments`	$71.00K	USD	Annual
Proceeds from PPP loan	`ProceedsFromPaycheckProtectionProgramLoan`	-	USD	Annual
Proceeds from PPP loan	`ProceedsFromPaycheckProtectionProgramLoan`	$1.14M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$22.80M	USD	Annual
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$47.87M	USD	Annual
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$15.74M	USD	Annual
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-14.93M	USD	Annual
At beginning of the year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$23.77M	USD	Point-in-time
At beginning of the year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.03M	USD	Point-in-time
At beginning of the year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.84M	USD	Point-in-time
At end of the year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$23.77M	USD	Point-in-time
At end of the year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.03M	USD	Point-in-time
At end of the year	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$8.84M	USD	Point-in-time
Cash paid for interest	`InterestPaidNet`	$171.00K	USD	Annual
Cash paid for interest	`InterestPaidNet`	$209.00K	USD	Annual
Common stock issued for acquisition of Insight Genetics	`CommonStockIssuedForAcquisition`	-	USD	Annual
Common stock issued for acquisition of Insight Genetics	`CommonStockIssuedForAcquisition`	$5.00M	USD	Annual
Initial fair value of contingent consideration at acquisition date	`InitialFairValueOfContingentConsiderationAtAcquisitionDate`	-	USD	Annual
Initial fair value of contingent consideration at acquisition date	`InitialFairValueOfContingentConsiderationAtAcquisitionDate`	$11.13M	USD	Annual
Holdback liability	`HoldbackLiability`	$600.00K	USD	Annual
Holdback liability	`HoldbackLiability`	-	USD	Annual
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability	`CapitalExpendituresIncurredButNotYetPaid`	-	USD	Annual
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability	`CapitalExpendituresIncurredButNotYetPaid`	$2.05M	USD	Annual
Accounts receivable from agent for at-the-market sales of common stock, net of financing costs	`AccountsReceivableFromAgentForAtthemarketSalesOfCommonStockNetOfFinancingCosts`	$262.00K	USD	Annual
Accounts receivable from agent for at-the-market sales of common stock, net of financing costs	`AccountsReceivableFromAgentForAtthemarketSalesOfCommonStockNetOfFinancingCosts`	-	USD	Annual
Issuance of common stock in lieu of cash for payment of board fees and deferred salaries	`StockIssued1`	-	USD	Annual
Issuance of common stock in lieu of cash for payment of board fees and deferred salaries	`StockIssued1`	$169.00K	USD	Annual
Deferred final commitment fee for bank loan	`DeferredFinalCommitmentFeeForBankLoan`	$200.00K	USD	Annual
Deferred final commitment fee for bank loan	`DeferredFinalCommitmentFeeForBankLoan`	-	USD	Annual

Stockholders Equity 27 line items

Line Item	Tag	Value	Unit	Period
Balance	`StockholdersEquity`	$3.42M	USD	Point-in-time
Balance	`StockholdersEquity`	$30.84M	USD	Point-in-time
Balance	`StockholdersEquity`	$33.48M	USD	Point-in-time
Net loss	`NetIncomeLoss`	$-22.43M	USD	Annual
Net loss	`NetIncomeLoss`	$-29.93M	USD	Annual
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$3.00M	USD	Annual
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensationGross`	$5.07M	USD	Annual
Sale of common shares	`StockIssuedDuringPeriodValueNewIssues`	$48.85M	USD	Annual
Sale of common shares	`StockIssuedDuringPeriodValueNewIssues`	$18.34M	USD	Annual
Sale of common shares, shares	`StockIssuedDuringPeriodSharesNewIssues`	-	shares	Annual
Sale of common shares, shares	`StockIssuedDuringPeriodSharesNewIssues`	-	shares	Annual
Financing costs paid to issue common shares	`StockIssuedDuringPeriodValueOther`	$-3.32M	USD	Annual
Financing costs paid to issue common shares	`StockIssuedDuringPeriodValueOther`	$-58.00K	USD	Annual
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$943.00K	USD	Annual
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$1.42M	USD	Annual
Exercise of stock options, shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	-	shares	Annual
Issuance of warrants	`StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants`	$370.00K	USD	Annual
Sale of common shares under at-the-market transactions	`StockIssuedDuringPeriodValueOfSaleOfCommonSharesUnderAtthemarketTransactions`	$2.73M	USD	Annual
Financing costs for at-the-market sales	`StockIssuedDuringPeriodValueFinancingCostsForAtthemarketSales`	$-82.00K	USD	Annual
Shares issued upon vesting of RSU, net of shares retired to pay employees' taxes	`SharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxes`	$-15.00K	USD	Annual
Shares issued upon vesting of RSU, net of shares retired to pay employees' taxes, shares	`SharesIssuedUponVestingOfRsuNetOfSharesRetiredToPayEmployeesTaxesShares`	-	shares	Annual
Issuance of common stock in lieu of cash for payment of board fees and deferred salaries	`StockIssuedDuringPeriodValueIssuedForServices`	$169.00K	USD	Annual
Issuance of common stock as partial consideration for Insight Genetics, Inc. acquisition	`StockIssuedDuringPeriodValueAcquisitions`	$5.00M	USD	Annual
Issuance of common stock as partial consideration for Insight Genetics, Inc. acquisition, shares	`StockIssuedDuringPeriodSharesAcquisitions`	-	shares	Annual
Balance	`StockholdersEquity`	$3.42M	USD	Point-in-time
Balance	`StockholdersEquity`	$30.84M	USD	Point-in-time
Balance	`StockholdersEquity`	$33.48M	USD	Point-in-time

Comprehensive Income 6 line items

Line Item	Tag	Value	Unit	Period
NET LOSS	`NetIncomeLoss`	$-22.43M	USD	Annual
NET LOSS	`NetIncomeLoss`	$-29.93M	USD	Annual
Other comprehensive loss, net of tax	`OtherComprehensiveIncomeLossNetOfTax`	-	USD	Annual
Other comprehensive loss, net of tax	`OtherComprehensiveIncomeLossNetOfTax`	-	USD	Annual
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-29.93M	USD	Annual
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-22.43M	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.